A rare, malignant neoplasm mainly affecting men in the fifth decade of life, that usually arises in the nose, paranasal sinuses, orbits or upper airway, and that can present with a nasal mass, nasal b...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding extranodal nasal NK/T cell lymphoma is largely due to its rarity, which affects fewer than 1 in 100,000 people. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to establish a clear genetic or phenotypic profile.
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
There are currently 41 active clinical trials investigating various treatment options for extranodal nasal NK/T cell lymphoma. Notably, pralatrexate is an FDA-approved orphan drug for this condition, while several other drugs are in development. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=extranodal%20nasal%20NK%2FT%20cell%20lymphoma.
Actionable guidance for navigating care for extranodal nasal NK/T cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding extranodal nasal NK/T cell lymphoma is largely due to its rarity, which affects fewer than 1 in 100,000 people. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to establish a clear genetic or phenotypic profile.
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
There are currently 41 active clinical trials investigating various treatment options for extranodal nasal NK/T cell lymphoma. Notably, pralatrexate is an FDA-approved orphan drug for this condition, while several other drugs are in development. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=extranodal%20nasal%20NK%2FT%20cell%20lymphoma.
Actionable guidance for navigating care for extranodal nasal NK/T cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding extranodal nasal NK/T cell lymphoma is largely due to its rarity, which affects fewer than 1 in 100,000 people. This rarity results in fewer systematic clinical studies and comprehensive data collection, making it challenging to establish a clear genetic or phenotypic profile.
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
There are currently 41 active clinical trials investigating various treatment options for extranodal nasal NK/T cell lymphoma. Notably, pralatrexate is an FDA-approved orphan drug for this condition, while several other drugs are in development. For more information on active trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=extranodal%20nasal%20NK%2FT%20cell%20lymphoma.
Actionable guidance for navigating care for extranodal nasal NK/T cell lymphoma
To navigate your care effectively, seek a hematologist or oncologist with experience in treating rare lymphomas, particularly NK/T cell lymphomas. Consider participating in clinical trials, as they may offer access to cutting-edge treatments. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can provide additional support and information. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 10 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.